Delivery Order SPE2DB22D2108-SPE2DB25FU5YN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,881.89 to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on July 28, 2025, with a completion date of July 29, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used in the treatment of cardiac arrhythmias, reflecting the pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,947.74 to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used in the treatment of atrial fibrillation, supporting the military...
- The Defense Logistics Agency awarded a delivery order valued at $11,496.80 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Multaq 400 mg tablets (60-count packages). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract calls for delivery by August 6, 2025, and performance will occur at the contractor's Conshohocken facility. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,234.92 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-unit package). This firm fixed-price, non-set-aside contract was awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used in the management of atrial fibrillation, representing a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $67,678.99 for 60-count tablets of Multaq 400 mg on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used in the treatment of atrial fibrillation, representing a critical...
- The Defense Logistics Agency awarded a $3,296.73 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Multaq 400 mg tablets (60 count). This firm fixed-price, non-set-aside contract is scheduled for completion by September 9, 2025, with fulfillment occurring at the contractor's Conshohocken, Pennsylvania facility. Multaq is an antiarrhythmic medication used in the treatment of atrial fibrillation, representing a critical pharmaceutical supply for military and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,368.45 for 60-tablet units of Multaq 400 mg on June 13, 2025, with completion scheduled for June 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used in cardiac care, reflecting the pharmaceutical supply requirements...
- The Defense Logistics Agency awarded a delivery order valued at $10,061.44 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. Multaq is a cardiovascular medication used in the treatment of atrial fibrillation, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count packages) under a firm fixed-price contract valued at $3,337.56. The order was competitively awarded without set-aside provisions and is scheduled for completion by July 25, 2025. Multaq is an antiarrhythmic medication used in the treatment of atrial fibrillation, reflecting the pharmaceutical distributor's role in supplying critical medications to federal...
- The Defense Logistics Agency awarded a $51,938.18 delivery order to AmerisourceBergen Drug Corp for 60-tablet units of Multaq 400 mg tablets, a pharmaceutical product used in cardiac arrhythmia management. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 13, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5YNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,403.81 to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on September 24, 2025, with completion expected by September 25, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used to maintain normal heart rhythm in patients with certain cardiac conditions, reflecting the Defense Logistics Agency's pharmaceutical supply requirements for military and veteran healthcare systems. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's track record of consistent delivery orders with firm fixed pricing demonstrates its capability to fulfill federal pharmaceutical requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.4k | 9/24/25 |